Podcasts about catalent

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Jeremie Trochu, CEO at Ardena. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jeremie, covering: The value of hitting the road and getting in front of clients, helping build several career-critical skills The big decision to leave med-tech giant GE and move to an ambitious, growing CDMO called...Catalent How the stars aligned to move back to Europe and join Ardena as CEO...and the secret sauce behind its suite of integrated development capabilities A transformational acquisition of Catalent's Somerset, NJ facility to help take Ardena to the next level as a global CDMO The importance of remembering that we are part of a cyclical industry and must ride out the lows, but we must remain adaptive and bullish about the market's growth Why VUCA (volatility, uncertainty, complexity, ambiguity) is inevitable Jeremie joined Ardena as Chief Executive Officer in June 2024. He brings an extensive knowledge of the life sciences and CDMO industry and a proven track record of success in the biopharma sector. He has 20 years of experience building and growing businesses globally, expanding into new markets, and leading large-scale transformations in publicly traded and privately held companies.  Jeremie was previously part of the team that helped transform Catalent from a private equity spinoff into a publicly traded global CDMO. During his tenure there, he led multiple companies' successful acquisitions and integrations. He holds a master's degree in Business Administration from EMLyon, France. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

“AI doesn't have to be the first port of call. Many organisations still need to focus on the paper-to-glass journey before they can think about more advanced technologies” Vishnu Dwadasi, Director of Life Sciences at West Monroe, brings extensive experience across pharmaceutical operations, consulting and business development from both the sponsor and CDMO sides. His career path through companies including Catalent, BioDuro, PII and now West Monroe has given him unique insights into the evolving pharmaceutical outsourcing landscape.In the latest PharmaSource podcast episode, Vishnu shares his perspective on how private equity investments are reshaping the CDMO landscape, post-merger integration challenges, and the realistic pace of digital transformation within pharmaceutical manufacturing organisations.Read the article

Lisata Therapeutics Inc (NASDAQ:LSTA) chief medical officer Dr Kristen Buck discussed the company's newly-announced research license agreement with Catalent with Proactive's Stephen Gunnion. Buck shared insights into Lisata's preclinical evaluation of certepetide using Catalent's SMARTag antibody-drug conjugate (ADC) platform.. She explained that Catalent would assume all R&D costs, while Lisata provides consulting and stands to receive both upfront and potential milestone payments. Certepetide is described as a unique cyclic non-amino acid peptide, designed to bind to receptors commonly found on solid tumors. Upon binding, it transforms to activate a transport mechanism that boosts therapeutic penetration. "It can work with current therapies and emerging therapies," Buck said, emphasizing its compatibility and favorable safety profile. Buck further discussed the growing relevance of ADCs in oncology. She described ADCs as “biological missiles,” targeting tumors while minimizing harm to healthy tissues. When combined with certepetide, ADCs benefit from deeper tumor penetration and potential immunomodulation, making treatment more effective. The company expects initial data from this collaboration before the end of Q2 2025. Positive results could lead to a deeper relationship with Catalent. Visit Proactive's YouTube channel for more company interviews and updates. Don't forget to like this video, subscribe to the channel, and enable notifications so you never miss future content. #LisataTherapeutics #KristenBuck #Certepetide #AntibodyDrugConjugates #ADC #OncologyInnovation #CancerResearch #Catalent #BiotechNews #TumorTargeting #ImmunoOncology #SMARTagPlatform

Megan Gluth, CEO of Catalent, a leading US chemical distributor, shares her journey from overcoming alcohol addiction to becoming a successful entrepreneur. Megan discusses her early struggles, including being kicked out of college and starting over in community college. She highlights the importance of taking responsibility and the impact of her partner's illness on her life. Megan emphasizes human-centered capitalism, focusing on profitability while prioritizing employee dignity and well-being. She advocates for authentic leadership, transparency, and supporting employees through personal challenges. Megan's story underscores the power of resilience, honesty, and creating a culture of care in business. Listen to her story today and choose which action principle resonates with you the most...then schedule it in your calendar!Action PrinciplesPick one to do this week:Allow consequences to happen. Look at areas where you may shield yourself or others from the consequences of choices. Allow those consequences to happen. ACTION: Write down why you should stop shielding someone (or yourself) to remind you when you're tempted to intervene.Prioritize your MVAs. Identify activities you're doing that don't matter as much and eliminate one of them to focus on more valuable things. ACTION: Pick one lower-value activity and commit to replacing it with something more valuable.Give back. As you succeed in your career, look for ways to do good and contribute to others' lives. ACTION: Choose an activity or person you want to help and schedule the first step to making it happen.Be honest. Be your own "chief truth teller" and strive for brutal honesty in your self-reflection. ACTION: Schedule time for reflection and evaluate your goals quarterly.Guest ResourcesLearn more about Megan Gluth at MeganGluth.com.Suggested LinkedIn Learning Course:Time Management FundamentalsDave Crenshaw develops productive leaders in Fortune 500 companies, universities, and organizations of every size. He has appeared in Time magazine, USA Today, FastCompany, and the BBC News. His courses on LinkedIn Learning have been viewed tens of millions of times. His five books have been published in eight languages, the most popular of which is The Myth of Multitasking—a time management bestseller. As an author, speaker, and online instructor, Dave has transformed the lives and careers of hundreds of thousands around the world. DaveCrenshaw.com

Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in Pharma and Biotech world.In 2024, the biopharma industry experienced both successes and setbacks in the field of neuroscience drug development. Companies like Bristol Myers Squibb, Eli Lilly, and AbbVie saw highs and lows throughout the year. Despite a still-tight business environment, there were some breakthroughs in the industry. Layoffs continued to be a trend, with companies like Bayer, Bristol Myers Squibb, and Johnson & Johnson cutting hundreds or thousands of employees. Clinical trial flops were also prevalent, especially in the neuro space where success rates are particularly low. Mergers and acquisitions remained relatively small in 2024, with Novo Holdings' acquisition of Catalent being the largest deal at $16.5 billion. The year also saw significant advancements in areas such as immuno-oncology, obesity clinical programs, and next-generation oncology drug classes. Additionally, there were legal challenges and regulatory developments that impacted the industry. The FDA approved landmark drugs and therapies throughout the year, including Lilly's GLP-1 for sleep apnea. Job opportunities in the biopharma industry continued to be available across various roles and companies.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Merck has entered the obesity pill race with a $2 billion deal with Hansoh, allowing them to compete in the crowded oral GLP-1 space. The FDA issued warning letters against GLP-1 compounders, and the EMA will investigate the eye risk for Novo Nordisk's Ozempic. Novo has also collaborated with Photys to add a novel approach to their cardiometabolic pipeline. Intelligencia AI accurately predicted high-potential biotechs before the ASH conference, showcasing the reliability of its predictive AI methodology. Tenaya stock crashed due to underwhelming data on cardio gene therapy, with a focus on scaling in 2024. Manufacturing has become the hottest target in biopharma, with all of pharma vying for capacity and talent. AbbVie's Humira held 105 patents, preventing biosimilar competition for over 20 years, prompting discussions on policy reforms to prevent unjust extensions of drug monopolies. Moderna investors are advised to hold after a steep drop in 2024. The year saw cautious IPOs, restraint, and breakthroughs. BMS' cost-cutting campaign is in progress, while AbbVie continues its deal-making spree. Lilly and Pfizer executives express an optimistic outlook. Layoffs occurred at Outlook Therapeutics. Novo Holdings successfully closed its $16.5 billion acquisition of Catalent, despite facing pressure from various stakeholders to block the deal. The acquisition was approved by both the European Commission and the Federal Trade Commission, raising concerns about competition in the CDMO sector.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Danish regulators have raised concerns about a rare eye disease associated with Novo Nordisk's GLP-1 drug, Ozempic, prompting a request for a formal EU review. The FTC has approved Novo Holdings' acquisition of Catalent, allowing the deal to proceed. Bristol Myers Squibb is aiming to reduce costs by $1.5 billion by 2025, while PepGen is facing an FDA hold on its Duchenne muscular dystrophy treatment trial. Intelligencia AI's accurate pre-ASH predictions for biotechs demonstrate the reliability of their AI methodology.In other news, there are advancements in molecular glue degraders, AbbVie continues its deal-making spree, Novo Nordisk reaffirms its commitment to a rare disease production facility, and there are ongoing challenges with drugs targeting the amyloid hypothesis. Layoffs at Editas and FDA approvals for Neurocrine and Checkpoint are also making headlines.

Da den sidste sten blev ryddet af vejen for Novos store fabriksopkøb hos amerikanske Catalent, blev en stor udfordring samtidig fjernet for den danske medicinal-gigant. Med opkøbet kan Novo nemlig endnu hurtigere give ikke mindst vægtabshungrende amerikanere og europæere deres medicin. Hør den Finans Lyn-analyse, hvor du kan blive klogere, hvor stor betydningen af godkendelsen for Novos seneste kæmpe handel. Og hvad det har af konsekvenser for koncernen, at den nu skal punge ud med de mange milliarder, men samtidig kan se frem til endnu flere. Gæst: Nick Sturm, journalist med fokus på Novo Nordisk og medicinalindustrien. Vært: Mads Ring. Producer: Kasper Søegaard.See omnystudio.com/listener for privacy information.

Dagens erhvervsoverblik: Pensiondanmark anklages for snyd i milliardudbud om elfærger. Novos opkøb af amerikanske Catalent er blevet godkendt af alle relevante myndigheder. Lave renter er på vej til F-kort-lånere, der længe har haltet bagefter renteniveauet på fastforrentede lån. Anti-woke ETF er på vej til aktiemarkederne.  Vært: Frederik Vincent (frvi@borsen.dk) 

Send us a texthttps://www.onthepen.com/post/novo-nordisk-catalent-deal-approvedSupport the showOur Book Has Been Released!Decoding GLP-1: A Guide for Friends and Family of Those On The PenBuy Here: https://amzn.to/3Dc66d4DNF10 Peptide Supplement I Use: https://integrativepeptides.com/AFFILITATES/OTPUSE CODE "OTP10" to save 10%. A small commission is paid back to support On The Pen!MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT:Venmo: OnThePenCa$h App: ManOnMounjaroBECOME A MEMBER:https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:   The good — EU approves Novo-Catalent acquisition The bad — CDMO National Resilience announces layoffs The ugly — FDA investigates blood cancer reports in gene therapy patients

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.J&J and Legend have released new Phase III data for their drug Carvykti, showing nearly 90% of patients had no detectable cancer cells after treatment. This data could help them fend off competition from emerging CAR T therapies like Gilead and Arcellx's Anito-cel. Biontech also has promising breast cancer data for their drug BNT327, while Moderna's RSV vaccines are facing safety concerns. Meanwhile, there is pushback against IRA's controversial 'pill penalty'. Opportunities to become a US Pharmacopeia expert volunteer are available. In the biotech industry, Acelyrin terminated its drug Izokibep after failed Phase IIB/III data, Cellectar downsized by 60%, and M&A spending has been small this year.Pharma dealmaking in 2024 has mostly stayed under $5 billion, with the exception of Novo Holdings' acquisition of Catalent for $16.5 billion. The proposed EPIC Act, which aims to give small molecule drugs the same protection against price negotiation as biologics, faces challenges due to concerns over balancing the federal budget. The biotech IPO class of 2024 has struggled, with many companies tumbling from their original offer price after going public. Novo and Catalent's deal has received EU approval, Lilly is investing $3 billion in a Wisconsin site, and GSK is making agreements to further their presence in neurology. Carisma Therapeutics is cutting staff and reprioritizing their pipeline, while Relmada is exploring strategic alternatives after a failed asset in depression. Cellectar is downsizing by 60% as they explore options for their cancer drug.

Send us a textSupport the showDNF10 Peptide Supplement I Use: https://integrativepeptides.com/AFFILITATES/OTPUSE CODE "OTP10" to save 10%. A small commission is paid back to support On The Pen!MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT:Venmo: OnThePenCa$h App: ManOnMounjaroBECOME A MEMBER:https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join

This week, GSK and Gilead and Arcellx presented key data at the American Society of Hematology (ASH) annual meeting as they vie for a competitive advantage in multiple myeloma. Meanwhile, Vertex unveiled positive long-term data for its CRISPR Therapeutics–partnered gene therapy Casgevy in sickle cell disease—results BMO Capital Markets analysts said should help Casgevy keep its edge over bluebird bio's Lyfgenia. On that note, Casgevy and Lyfgenia have a new outcomes-based payment model after the Centers for Medicare and Medicaid Service (CMS) said both companies have agreed to participate in a voluntary program to improve access to the gene therapies. Speaking of access, Eli Lilly and Novo Nordisk both announced significant manufacturing investments aimed at shoring up production of their diabetes and weight loss blockbusters tirzepatide and semaglutide. And in related news, the European Commission gave its blessing to Novo Holdings' controversial acquisition of contract manufacturing firm Catalent. Elsewhere, AbbVie got a much-needed win for Cerevel-acquired Parkinson's disease therapy tavapadon—a month after the deal's cornerstone asset emraclidine failed in schizophrenia—while uniQure announced it has aligned with the FDA on “key elements” of the accelerated approval pathway for its investigational gene therapy for Huntington's, AMT-130.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The FDA's accelerated approval pathway, established in 1992, has allowed over 200 new drugs to come to market based on surrogate endpoints. While many products have later received full FDA approval, recent withdrawals like Pfizer's Oxbryta and Takeda's Exkivity have raised concerns about the risks of this pathway. Despite some high-profile failures, the program has a strong track record, with over half of accelerated approvals converting to full approval. The pathway has been used primarily for cancer treatments but is now expanding to other disease areas like neurological and rare diseases. Recent failures of confirmatory trials for drugs like Sarepta's Elevidys have prompted experts to call for tighter timelines and better biomarkers for surrogate endpoints in order to improve the program. The future of the accelerated approval pathway is under scrutiny, with questions arising about how often it should be used and what areas it should focus on next.AbbVie's Tavapadon showed improvement in motor and daily living complications in a Phase III trial, following the failure of another key cerevel asset, Emraclidine. Relmada Therapeutics is considering strategic alternatives, including a potential sale, after halting two Phase III trials for a major depressive disorder drug. Other news includes BioAge discontinuing a Phase II obesity study, Merck's promising anti-ROR1 ADC data for lymphoma treatment, and Novo and Catalent's $16.5 billion deal receiving EU approval. Additionally, Vertex and Beam report advances in SCD cell and gene therapies, while evidence grows for the potential of GLP-1s in Alzheimer's disease.Recent studies have shown that GLP-1 receptor agonists, commonly used for weight loss and diabetes, may have potential in treating Alzheimer's disease. Phase III results from Novo Nordisk are expected next year. Additionally, amylin analogs are emerging as a potential alternative or complement to GLP-1 receptor agonists for weight loss with a cleaner tolerability profile. Other news includes a weight loss victory claimed by Lilly over Novo in a head-to-head study, FDA action alerts, and promising cancer therapies from companies like AstraZeneca and Merus. The FDA is also investigating the safety of Bluebird's gene therapy Skysona for hematologic malignancies. Applied Therapeutics recently faced a crash after FDA rejection of a rare disease drug. Overall, the potential of GLP-1s in Alzheimer's disease and the emergence of amylin analogs in weight loss are significant developments in the biopharma industry.

Oprør i Syrien, Assad flygtet til Moskva. Tysk topøkonom fælder hård dom. EU godkender Novos køb af Catalent. SVM-ministre vil gå til kamp mod bureaukrati fra EU. Jobfesten var tilbage i USA i november. Aktierekorder i USA. Vært: Lasse Ladefoged (lala@borsen.dk) 

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Amgen's obesity candidate, maritide, faced new safety concerns related to bone density, causing a drop in the company's stock. Biogen's shares have also plummeted due to issues such as a slow launch for their Alzheimer's medicine and a lackluster pipeline. Meanwhile, the biotech company Metsera raised significant funds for their long-acting GLP-1 drug despite competition in the weight loss space. Additionally, Kezar's autoimmune drug faced a second FDA clinical hold, and Syros experienced a significant drop in stock value due to a late-stage MDS failure. Novo's deal with Catalent is seen as a significant moment for the CDMO sector. These developments indicate ongoing challenges and opportunities in the biotech industry.Biogen's shares have dropped by 36% in 2024 due to factors such as a slow launch for Alzheimer's medicine Leqembi and a lackluster pipeline. The Novo-Catalent deal is seen as a defining moment for the CDMO industry, with concerns about consolidation limiting competition but also providing opportunities for smaller-scale CDMDs to find new partners. Other news includes Amgen facing bone density safety concerns for Maritide, AbbVie shares plummeting due to a failed schizophrenia asset, and Bayer's CEO admitting that their earnings are not looking good. In the biopharma job market, positions such as Executive Director of Biologics Analytical Research and Development at Merck & Co. and Vice President of Global Program Head - Ophthalmology at Regeneron Pharmaceuticals are available.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Eisai's sales of its Alzheimer's disease therapy Leqembi have disappointed analysts, leading the company to lower its fiscal 2024 guidance. The underwhelming sales are attributed to barriers such as coverage, infusion centers, and time to diagnosis. In other news, Pfizer has made a $1 billion commitment in China to boost innovation and target the Chinese market, while AstraZeneca's China head has been taken into custody by Chinese authorities for reasons that remain unclear. There is also a dispute between Lilly and Novo over Catalent's GLP-1 work, as regulators review Novo Holdings' buyout of Catalent and the work the contract drug manufacturer may or may not be performing for Eli Lilly remains contentious.Additionally, a gene therapy webinar on successful preparation for scaling gene therapy processes is highlighted. Other news includes the impact of a Trump victory on the biopharma industry, cell therapy biotechs shifting focus to autoimmune expertise, and updates on Lilly's Q3 performance and more.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Analysts are expressing mixed reactions to Donald Trump's election victory. There are potential positives for the biopharma industry, such as a more friendly FTC for M&A deals. However, concerns have been raised about what role Robert F. Kennedy, Jr. might play in healthcare under Trump's administration. Moving on to recent news, Catalent missed fiscal Q1 revenue expectations and there is growing opposition to Novo Holdings' acquisition of Catalent. Novo Nordisk also missed overall Q3 revenue expectations, but exceeded sales forecasts for the weight loss drug Wegovy. Gilead and Arcellx are highlighting the best-in-class potential for CAR T therapy in multiple myeloma. Overall, Trump's win poses more questions than answers for the biopharma industry, with uncertainties about the future regulatory environment and potential impacts on healthcare policies.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with: Dirk Lange, CEO at Pyramid Labs Brett Alderson, President & Site Leader at NovaCina John Cameron, Director, Global Injectables Platform at Corden Pharma Janet Hoogstraate, CEO at NorthX Biologics Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Dirk, Brett, John & Janet, focusing on: Maximizing GLP-1 manufacturing capacity: Discussing Novo Nordisk's recent acquisition of Catalent's manufacturing facilities to bolster GLP-1 production capabilities Industry consolidation: What this acquisition means for the pharmaceutical outsourcing industry and its impact on competition among CDMOs Meeting surging demand: Exploring how this move positions Novo Nordisk to respond to the rapidly increasing demand for GLP-1 receptor agonists, like those used in diabetes and obesity treatments Strategic manufacturing: The implications of integrating Catalent's capabilities into Novo Nordisk's operations and what it means for the broader CDMO sector With GLP-1 drugs at the forefront of diabetes and obesity treatment, Novo Nordisk's strategic acquisition of Catalent aims to strengthen its supply chain and boost production capacity to meet global demand. Our guests provide in-depth insights into how this acquisition could shape the future of drug development and outsourcing across the industry.   This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter's comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!   Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.  

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. A study has found that Novo Nordisk's semaglutide may reduce the risk of Alzheimer's disease by 40% to 70%. Roche has entered a potential $1 billion gene therapy deal with Dyno Therapeutics, focusing on neurological diseases. Off-label prescribing of GLP-1 receptor agonists for type 1 diabetes has increased, despite lack of FDA approval. Viking Therapeutics plans to accelerate the development of an obesity drug with two Q4 catalysts. Trilink Biotechnologies has expanded its mRNA synthesis services offerings for screening studies. The USP aims to double its volunteer applicant pool, while a CDC panel recommends pneumococcal vaccines for adults aged 50-64. Updates on companies like Catalent, Sangamo, and Moderna are also included in today's news. Additionally, the FDA has approved Pfizer's Abrysvo as the first RSV vaccine for younger adults.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Roche CEO opposes Novo Holdings' acquisition of Catalent, urging for it to be blocked. Roche exceeded Q3 sales expectations, driven by the success of drugs like Ocrevus and Vabysmo. Pfizer's RSV vaccine has been approved by the FDA for a wider adult population. Novo Nordisk has raised concerns with the FDA about the complexity of compounders producing its drug Semaglutide. Alto Neuroscience's depression treatment did not meet expectations in a mid-stage trial, echoing Acelyrin's setback last year. Trilink Biotechnologies has launched customized mRNA sets for screening studies. Updates on Trodelvy's withdrawal for bladder cancer, Sage Therapeutics' layoffs, and more are also featured. Pfizer has downsized with 75 job cuts at a North Carolina site. Opportunities in the life sciences industry are also highlighted.Thank you for listening to Pharma and Biotech Daily, stay tuned for more updates.

Last week, Gilead withdrew Trodelvy in bladder cancer after the antibody-drug conjugate failed to meet the primary endpoint in a confirmatory study. This follows Pfizer's recent withdrawal of another therapy that had earned FDA accelerated approval, Oxbryta for sickle cell disease. With few other options available to patients, BioSpace took a look at 5 sickle-cell candidates currently in clinical trials.   Following a disappointing Alzheimer's readout, the company's third neuro stumble in six months, Sage Therapeutics will lay off over 165 employees—about 33% of its workforce. The company is reporting Q3 earnings on Oct. 29.  On a more positive note, Vertex reported full Phase III data this week for its non-opioid pain treatment, su-zetri-gine. If approved, suzetrigine, which has a PDUFA date of Jan. 30, 2025, would be the first new class of acute pain medicine in more than two decades. And on Monday, a company that never leaves the news, Novo Nordisk, announced positive results from a cardiovascular study with its oral version of semaglutide, Rybelsus. In other Novo news, scrutiny around Novo Holdings' acquisition of Catalent is heating up with a coalition of unions, consumer groups and public interest organizations last week expressing their concerns about the buyout. This prompted BioSpace to unpack the unique structure of the collection of organizations that is Novo. Finally, Sanofi is having a busy month, securing the sale of its healthcare unit Opella and separately paying approximately $326 million to obtain a 16% stake in European radiopharma biotech Orano Med. Radiopharma is skyrocketing in popularity, and some companies are even trying to marry it with another hot therapeutic spaces: antibody-drug conjugates. Could radiolabeled ADCs overcome some of the side effects of radiation treatments, speed up treatment times and enable lower doses than traditional therapies?

Send us a textLilly Lawsuits: https://www.onthepen.com/post/eli-lilly-zepbound-tirzepatide-lawsuitsCatalent Merger: https://www.businesswire.com/news/home/20241020996199/en/Catalent-Issues-Open-Letter-to-Customers-Regarding-Pending-Acquisition-by-Novo-HoldingsOnthepen.TVSupport the showMY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT:Venmo: OnThePenCa$h App: ManOnMounjaroBECOME A MEMBER:https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The FDA has paused Novavax's investigational flu and COVID-flu vaccines due to a serious adverse event of motor neuropathy. This affects their COVID-flu combo and standalone flu vaccines, which were about to enter phase III testing. Meanwhile, Takeda has decided to terminate its partnership with Wave on a Huntington's disease program after investing $260 million. Novavax shares have slid due to the FDA pause, while GSK is suing Moderna for patent infringement on COVID-19 and RSV vaccines. Sanofi is also preparing to sell its consumer healthcare business.Artificial intelligence (AI) is playing a significant role in accelerating innovation in biopharma, particularly in drug development. While AI is infiltrating various stages of the process, it is not replacing human input entirely. One example of AI's impact is seen in Regeneron and Sanofi's Dupixent, which is expected to dominate the COPD biologics market with predicted revenues exceeding $6.5 billion within a decade. Additionally, Sanofi's move to sell its consumer healthcare business follows a trend among big pharma companies offloading such divisions.In the realm of biologics discovery, harnessing the power of AI and patent data can revolutionize the industry. Despite challenges related to limited access to high-quality, fair-compliant data, leveraging patent information can fill this gap and drive innovation in drug development. Takeda has walked away from its partnership with Wave Huntington after investing $260 million in the collaboration. J&J has announced Q3 earnings, including scrapping pipeline assets and raising full-year guidance. Novo's $16.5 billion buyout of Catalent faces scrutiny amid an FTC review, while GSK has sued Moderna for alleged patent infringement.Overall, the biopharma industry continues to evolve with the integration of AI, strategic partnerships, regulatory changes, and financial developments shaping its landscape.

It's that time again: earnings season. Q3 calls started out with a bit of a snore from J&J, which did beat analyst expectations but announced no big shakeups or surprises. As expected, the company saw shrinking revenue for its blockbuster Stelara, which just lost to Lilly's Omvoh in a head-to-head clinical trial in Crohn's disease. Last week, a concerning study was published regarding seven children who developed blood cancers after being treated with bluebird bio's gene therapy Skysona. This publication comes at a time when the company is struggling to regain its share price, which has dropped below the Nasdaq minimum bid price requirement. The bad news about Skysona also fits with another trend BioSpace covered this week: accelerated approvals gone wrong. In other news, Sanofi is following some of its pharma peers and looking to sell its consumer healthcare unit. This follows similar moves from J&J, which spun off Kenvue last year, as well as GSK, Pfizer and others. And Senator Elizabeth Warren (Mass.-D) is upping the pressure on Novo in relation to its acquisition of Catalent, penning a letter to the Federal Trade Commission voicing concerns about the potential effects of such a deal, should it go through. Finally, bispecific antibodies make a comeback in oncology.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Danish pharmaceutical company Lundbeck has announced a $2.6 billion deal to acquire Longboard Pharmaceuticals, gaining access to their epilepsy drug currently in late-stage development. The FDA's accelerated approval pathway has seen withdrawals and failures recently, despite having helped bring nearly 300 new drugs to market since 1992.In other news, Novo Nordisk has acquired Catalent's oral solids manufacturing facility in New Jersey, while Lilly's tirzepatide could face shortages leading to opportunities for compounders. Additionally, Pfizer has won FDA approval for a hemophilia therapy amid activist investor challenges, and Evonik is set to lay off up to 260 employees in Germany. Bluebird's gene therapy has been linked to blood cancers in children.The Institute for Cancer Research is researching preventive and regenerative medicine to extend healthy lifespan.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Roche has received regulatory approval for its breast cancer drug, inavolisib, for advanced breast cancer, projecting $2.3 billion in peak sales. This drug is seen as a potential competitor to Novartis' pi3k inhibitor piqray.Teva has agreed to pay $450 million in a settlement with the Department of Justice over kickback and price-fixing allegations. Upstream Bio raised $255 million in an IPO for inflammatory disease work, while Camp4 Therapeutics received $75 million for RNA-targeting drug development.Senator Elizabeth Warren has expressed concerns about Novo Nordisk's $16.5 billion acquisition of Catalent, warning that it could reduce competition in the market. Genscript is hosting the Biotech Global Forum 2025 on January 15, 2025, focusing on gene and cell therapy innovations.Stealth received support for ultra-rare disease drugs, Sanofi and Denali abandoned a multiple sclerosis study, and Lilly is facing challenges in its obesity clinical program. Layoffs have been announced at Medtronic, CareFusion, and Turnstone Biologics. For job opportunities in the biotech industry, Recursion, NKarta Inc., Foresight Diagnostics, and Insmed Incorporated are hiring for various positions.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Kent Payne, CEO at Aliri Bioanalysis.  Your host Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Kent, covering: Being exposed to scientific efficiencies early on in his career as a bench scientist, and what it took to bring a successful NDA to market The formative years of Catalent, and helping to establish its early biologics and bioanalysis capabilities He shares his core principles playbook for getting a company back on track and on a path for growth The value of getting scientists in front of the client to build relationships and demonstrate technical know-how The strong fundamentals that attracted him to Aliri, and having hot RNA therapeutic capabilities to offer the market How Aliri was formed through the merger of three well-established players in the bioanalytical space: Tandem Labs, Pyxant Labs, and ImaBiotech  Dr. Kent Payne is distinguished as a business operator and leader in sales, commercial manufacturing, and product development. He has extensive executive experience in M&A and successfully running start-up, growth, and turnaround businesses in Fortune 500 and Private Equity environments. Kent currently serves as the CEO of Aliri Bioanalysis (an Archimed investment company) and board director for GBI (a Signet Healthcare Partners company). He previously served as the CEO of BioDuro-Sundia, LLC (an Advent International company) Aliri Bioanalysis is celebrating the 30th anniversary of its operations in Salt Lake City, Utah, which coincidently, is also the location of the AAPS annual meeting this year.  Kent and team are marking this special occasion during the conference where they will showcase their technical expertise with over a dozen scientific posters and presentations.  He also wanted to let our listeners know that his team would be happy to host personal tours of their lab in Salt Lake to those attending the conference.  Simply email tours@aliribio.com to learn more. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Gil Roth, President of the Pharma & Biopharma Outsourcing Association (PBOA). Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Gil, covering: The evolution of the PBOA over the last decade, the impact of M&A on the Association, and building a safe place where CDMOs belong How the industry has evolved over the last few years after Covid, including harder times and areas of green shoots Why Gil believes Novo's purchase of Catalent is a black swan event and not a new megatrend A deeper dive into fine details of The BIOSECURE Act, and its potential impact on the CDMO space over the next 7-8 years The need to know market headwinds and tailwinds that you simply cannot ignore Gil Roth is the Founder and President of the Pharma & Biopharma Outsourcing Association (PBOA), a nonprofit trade group that advocates for the regulatory, legislative and general business interests of the CMO/CDMO sector. In this role, he brings CDMO perspectives and education to FDA, the US Congress, and other bodies, and brings CDMOs together to share best practices, develop policy positions, and provide briefings on government positions that impact that sector. He also organizes and hosts PBOA's annual members-only Meeting & Conference. Previously, he was the Founding Editor of Contract Pharma magazine. In his alleged free time, he produces a weekly cultural conversation podcast called the Virtual Memories Show (https://chimeraobscura.com/vm) Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Back in February, Novo Holdings laid out a $16.5 billion deal to snap up contract manufacturing giant Catalent. In this week's episode of "The Top Line," we dive into the current state and implications of the proposed buyout.   Fierce Pharma's Fraiser Kansteiner is joined by former FTC policy director David Balto. They discuss the likelihood of the deal going through, potential regulatory hurdles and what the transaction could mean for the greater CDMO landscape. To learn more about the topics in this episode:  Another day, another delay for Novo's Catalent acquisition as FTC imposes 'Second Request' Novo antes up $16.5B to poach CDMO giant Catalent amid Wegovy surge See omnystudio.com/listener for privacy information.

What's the biggest risk to the insane growth trajectory of GLP-1 pharmaceutical weight loss solutions? Explosive demand in the U.S. market has outstripped supply…causing prolonged shortages of these medications. GLP-1 market leaders, Novo Nordisk and Eli Lilly, have warned supply constraints would likely extend into late-2024. That has unfortunately increased the circulation of counterfeit versions through unregulated outlets that can carry serious health risks. But good news could be on the horizon…at least for the maker of Ozempic and Wegovy. Last month, Novo Nordisk announced intentions to acquire its primary contract manufacturer responsible for filling and packaging its GLP-1 injection pens…Catalent for $16.5 billion. While the move won't solve everything, it provides strategic flexibility to an existing supply network that includes another $8 billion spent on expanding manufacturing sites in France and Denmark. FOLLOW ME ON MY SOCIAL MEDIA ACCOUNTS ⁠⁠⁠⁠⁠⁠⁠⁠LINKEDIN⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠YOUTUBE⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠TWITTER⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠INSTAGRAM⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠FACEBOOK⁠⁠⁠⁠⁠⁠⁠⁠ --- Support this podcast: https://podcasters.spotify.com/pod/show/joshua-schall/support

This week's episode of “The Top Line” is the second part of a three-part series exploring the latest advancements in cell and gene therapy manufacturing. In this episode, Fierce Pharma's Fraiser Kansteiner interviews Delara Motlagh, head of cell therapy at Catalent; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle, CEO of Germfree. The conversation covers cell collection, the critical first step in advanced therapy manufacturing. They also discuss the importance of locking in process decisions early and how to effectively scale projects from the lab to the clinic and eventually to the market. Additionally, they talk about Germfree's recent asset acquisition from Orgenesis, which will allow the company to expand its mission of decentralized manufacturing. To learn more about the topics in this episode: Fulfilling the promise of cell & gene therapies through manufacturing (Part I) With new partnership, Galapagos takes decentralized CAR-T manufacturing quest nationwide Catalent opens cell therapy production site at Belgian 'center of excellence' After recent troubles, Catalent expands its biologics services platform  See omnystudio.com/listener for privacy information.

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:  The good —  Vertex submits NDA for CF drug The bad — MacroGenics reports patient deaths in prostate cancer ADC trial  The ugly — FTC extends review of Novo-Catalent deal

The obesity drug market has grown dramatically in the last few years, especially with the help of social media and influencers. The immense popularity of anti-obesity medications has transformed a health industry development into a cultural phenomenon. While this market has so much opportunity, it also faces supply issues and coverage gaps. Mindy and Jen are joined by Vynamic's Head of Life Sciences, Karen Baldry, and Head of Health Plans, Saurabh Raman, to talk about the growth and challenges obesity medications present for the health industry.Podcast Tags: healthcare, obesity, weight loss, diabetes, health services, health plans, life sciences  Source Links: What Is Ozempic and Why Is It Getting So Much Attention? We Know Where New Weight Loss Drugs Came From, but Not Why They Work What the Scientists Who Pioneered Weight-Loss Drugs Want You to Know Supply Updates about WegovyThe increase in appetite for obesity drugs Demand for GLP-1 drugs is growing. Here's why payers are hesitant to cover them for weight loss More than 4,000 ads for Ozempic-style drugs found running on Instagram and Facebook  Wegovy heart health data is promising — but insurers face long road, high cost to cover obesity drugs Medicare is barred from paying for weight-loss drugs like Wegovy. Lawmakers just took the first step to change that Cost isn't the only reason Medicare doesn't cover WegovyNew marketing push by Ozempic and others sparks body-positive backlash What You Need to Know About Compounded Versions of Popular Weight Loss Drugs Novo antes up $16.5B to poach CDMO giant Catalent amid Wegovy surge  Wegovy, other GLP-1s could lower heart disease: Study  Novo kidney trial finds Ozempic cuts cardiac deaths in diabetics  How Ozempic and Weight Loss Drugs Are Reshaping Denmark's Economy  Novo Nordisk's Wegovy bonanza looms large in Denmark  Big pharma's blockbuster obesity drug battle is just getting started, and it's headed for $100 billion  Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect  Ozempic vs Wegovy Obesity drug boom pushes Novo Nordisk shares to record high Popular use of obesity drugs like Ozempic could change consumer habits Panel – Jen Burke, Mindy McGrath, Karen Baldry, Saurabh Raman Research & Production – Adrea Cope, Everly Petruzzelli Recording & Editing – Mike Liberto, Rachel Skonecki For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

In this episode of Leveraging Leadership, host Emily Sander, a former Chief of Staff turned Executive Leadership Coach, sits down with Natalie Crohn, who has served as Chief of Staff at two different organizations. The pair share their experiences in the role, with topics from authenticity and networking to the handling of day-to-day challenges and strategic planning, there's plenty of insight to take away. Also, don't miss Natalie's unique Chief of Staff-themed cocktail recommendation. Hit subscribe to continue your leadership journey with us. Natalie Crohn on LinkedIn Natalie Crohn has expertly navigated a diverse professional journey, from social work to IT consulting, and ultimately, into a strategic Chief of Staff role. She initially started in healthcare, transitioned into IT consulting, and circled back to healthcare, gaining diverse expertise. Natalie discovered her passion for strategic management at Catalent, a biopharmaceutical company, and later expanded her skills as the Chief of Staff at Magellan Health and currently, Johns Hopkins Health. Alongside her career, Natalie actively champions organizational culture, diversity, and inclusion initiatives. Deemed an authentic leader, Natalie is always eager to learn, develop, and serve others. – – – – – Timestamps 00:57 Guest Introduction: Natalie Cron 01:27 Natalie's Journey to Chief of Staff 05:28 Transitioning Between Chief of Staff Roles 09:46 The Importance of Authenticity in Leadership 11:59 The Role of Coaching Fridays in Leadership Development 17:26 The Importance of Authenticity in the Workplace 24:12 Advice for New Chiefs of Staff 28:08 Tools for Staying Organized as a Chief of Staff 32:09 The Chief of Staff Cocktail: A Fun Analogy 33:21 Final Thoughts – – – – – Emily Sander is a C-suite executive turned leadership coach. Her corporate career spanned Fortune 500 companies and scrappy start-ups. She is an ICF-certified leadership coach and the author of two books, An Insider’s Perspective on the Chief of Staff and Hacking Executive Leadership. Emily works with early to senior executives to step into effective leadership with one-on-one coaching. Go here to read her story from seasoned executive to knowledgeable coach. Get your free Chief of Staff Skills Assessment Checklist here. Download your free Chief of Staff Toolkit here. To learn more about Emily and Next Level Coaching, click here. Follow Emily on LinkedIn | YouTube

Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world. French drugmaker Sanofi has announced positive results from a Phase II trial of its experimental drug frexalimab in relapsing multiple sclerosis (MS). The trial, published in the New England Journal of Medicine, showed that frexalimab significantly slowed disease activity in patients with relapsing MS. The drug targets a protein called CD40L, which is involved in the activation of immune cells that attack the protective covering of nerve fibers in patients with MS. Sanofi plans to continue clinical testing of frexalimab and aims for peak annual sales of $5 billion for the drug.In other news, biopharma companies Catalent, Aurinia, and Sandoz have recently announced staff cuts. Biospace is tracking these layoffs and providing updates on the latest industry developments.Moving on to funding news, biotech company Freenome has raised $254 million in a fundraising round led by Roche. Freenome is developing blood-based tests for cancer detection and aims to advance its tests as pivotal readouts approach. Another biotech company, Firefly Bio, has emerged from stealth mode with $94 million in Series A funding. Firefly Bio is focused on developing antibody-drug conjugates and protein degraders for targeted cancer therapies.Lastly, Bristol Myers Squibb is leading the future of protein degradation with its three-pronged approach to developing targeted protein degraders. The company aims to design next-generation degraders that can attack disease targets with precision and agility.These developments highlight the progress being made in the biopharma industry in areas such as multiple sclerosis treatment, cancer detection, targeted cancer therapies, and protein degradation.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Biogen is facing additional troubles as the Department of Justice (DOJ) and Securities and Exchange Commission (SEC) have issued subpoenas seeking more information. The DOJ is specifically looking into the company's overseas operations, while the SEC is investigating the launch of Biogen's now-discontinued Alzheimer's disease therapy, Aduhelm.In other news, the Federal Trade Commission (FTC) and Department of Health and Human Services (HHS) have launched a probe into the ongoing generic drug shortage. The investigation will focus on possible involvement of group purchasing organizations and drug wholesalers in exacerbating the shortage.Ipsen's Onivyde has been approved as a first-line treatment for metastatic pancreatic cancer. This marks the first new frontline treatment option in over 10 years for adults living with this type of cancer.Latigo Biotherapeutics has raised $135 million in a Series A funding round to enter the non-opioid pain medicine space. The company plans to develop its own Nav1.8 inhibitor for pain management.Bristol Myers Squibb is leading the future of protein degradation with its targeted protein degradation approach. The company aims to design next-generation degraders with precision, agility, and intention to attack disease targets.In other funding news, European-based venture capital firm Earlybird Health has closed a $186 million fund focused on cancer and neuroscience investments in biopharma. Additionally, ADC-focused ProfoundBio has raised $112 million in an oversubscribed Series B round.Brivant, a subsidiary of Roivant Sciences, has announced plans to shut down its MDS-focused division, Vant, following disappointing Phase I/II trial results.The FDA has pushed back the Prescription Drug User Fee Act (PDUFA) date for Rocket Pharmaceuticals' gene therapy for a rare blood disorder.Patients taking semaglutide have seen benefits after total hip replacement surgery, according to recent studies.In other news, Novo Nordisk has acquired Catalent's gene therapy manufacturing business for $1.2 billion.These are the top stories in the biopharmaceutical industry today.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Today we have some exciting news to share with you.## The biotech industry is gaining momentum in 2024, with emerging companies and their investors adapting to industry changes. Biopharma Dive is offering a trendline that explores this new sense of optimism and provides insights into the challenges and opportunities facing these companies. It covers topics such as the impact of biotech layoffs, AI in biotech, and more. This trendline is independently produced by Biopharma Dive's journalists and is made possible with the support of sponsors.## Biogen is facing challenges in obtaining complete information about its Alzheimer's drug, Leqembi, as its development partner Eisai is leading commercial efforts. Biogen CEO Chris Viehbacher mentioned that there are approximately 3,800 registered patients in the US for Leqembi. Two investors from GV discussed the reset of the biotech industry and building their next drug startups. Kalvista Pharmaceuticals announced the success of its late-stage study on a pill for hereditary angioedema. ProfoundBio raised $112 million in funding for its antibody-drug conjugate development. BioAge secured $170 million in funding for its obesity drug.## Health insurer Elevance has reportedly laid off thousands of employees since September. Alabama-based healthcare provider Baptist Health has filed a lawsuit against Humana, alleging underpayment in the Medicare Advantage program. The state of Washington is considering legislation to regulate hospital mergers. The University of Minnesota is planning to reacquire its medical center from Fairview Health Services. A data breach at an Oklahoma health system has potentially exposed personal information from nearly 2.4 million people. The Federal Trade Commission (FTC) has obtained a $195 million judgment against Simple Health for selling "sham" insurance.## Senseonics has gained expanded Medicare coverage for its implantable continuous glucose monitoring device. A study found that the revision rate for robotic knee replacement surgery is no better than traditional surgery. Several medtech companies have announced job cuts. The FDA seems inclined towards approving Abbott's Triclip. A study conducted by Masimo has found that pulse oximeters are accurate in black patients with low pulse strength.## Novo Nordisk's acquisition of Catalent is facing uncertainty due to manufacturing deviations at a Catalent facility. The weight loss market has been generating hype, but recent drug launches have flopped. Vituity offers clinical leadership and support for healthcare organizations. A webinar discusses the benefits of using a digital hub to improve access and outcomes in the healthcare industry.## Kyverna raised $319 million in an IPO, adding to the momentum of biotech companies going public. Gene editing biotech Metagenomi raised nearly $94 million in its IPO. Alys,

This week, Greg, Heather and Tyler discuss reaction to Novo Nordisk's purchase of Catalent and speculate on what that means for existing manufacturing contracts, customers and consequences with regulators; as well as discussion around the ongoing issues with drug shortages and manufacturing challenges and whether it the move will help accelerate manufacturing for Wegovy and Ozempic. Plus, what's next for Alzheimer's treatment following Biogen's withdrawal of Aduhelm? As mentioned in this episode: you can subscribe to ClinicaSpace for our latest special edition on Leqembi.

Dive deep into the Novo Nordisk and Catalent merger and how that will affect the GLP-1 market.

Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world. AstraZeneca is making a big move in the cell therapy manufacturing field. The company plans to invest $300 million in a new facility in Rockville, Maryland. This investment comes after AstraZeneca has made several deals in the therapeutic field, showing their commitment to advancing medical treatments. In other news, Kyverna, a developer of cell therapies for autoimmune diseases, has raised an impressive $319 million through its IPO. This makes Kyverna the fifth drug startup to go public in 2024. It's great to see so much interest and support for innovative treatments that can make a difference in patients' lives. Another exciting development is happening at Neurona, which has raised an additional $120 million for its brain disease cell therapies. This signals renewed interest from investors in this area of research, recognizing the potential for breakthrough treatments. It's encouraging to see financial support for advancements in brain disease therapies. We also have Alex Morgan from Khosla Ventures joining us today to discuss the challenges of biotech and the importance of solving drug delivery. It's crucial to find better ways to deliver medications to patients, ensuring their efficacy and safety. We look forward to hearing Alex's insights on this critical topic. Moving on, German biotech company BioNTech has partnered with Autolus to boost cell therapy manufacturing. This collaboration involves a $200 million investment by BioNTech in Autolus, giving them licensing options and access to supply infrastructure. It's great to see companies joining forces to accelerate progress in the field of cell therapy manufacturing. Lastly, Novo Holdings, a subsidiary of Novo Nordisk, has some big plans for expansion. They are set to purchase contract drug manufacturer Catalent for a whopping $16.5 billion. Additionally, Novo Nordisk will acquire three major Catalent factories for $11 billion to meet the increasing demand for their obesity and diabetes medicines. It's clear that Novo Nordisk is committed to ensuring patients have access to the treatments they need. That's all for today's episode of Pharma and Biotech Daily. Stay tuned for more important news and updates in the world of Pharma and Biotech. Have a great day!

In der neuesten Folge unseres Aktienpodcasts, präsentiert von Philipp und Marcel von Modern Value Investing, tauchen wir tief in die Welt der Künstlichen Intelligenz (KI) und analysieren die jüngsten Quartalszahlen führender Unternehmen. Erfahren Sie, wie Palantir als "Lionel Messi der KI" den Markt beeindruckt, warum Air Products & Chemicals trotz einer unter den Erwartungen liegenden Prognose eine Chance darstellen könnte, und wie Disney sich im Mediensektor mit einem innovativen Sport-Streaming-Deal positioniert. Wir diskutieren auch bedeutende Bewegungen im Pharmasektor, darunter die Übernahme von Catalent durch Novo Nordisk und Novartis' Kauf von MorphoSys, sowie den erfolgreichen Renk IPO, der neue Wachstumsmöglichkeiten im Verteidigungs- und Energiesektor eröffnet. Außerdem beleuchten wir die Herausforderungen und Chancen für Unternehmen wie BAT, die ihre Beteiligung in Indien verkaufen wollen, und Disney, das mit Vorschlägen für den Aufsichtsrat konfrontiert ist. Nicht zu vergessen die Expansion von Flixbus nach Indien, die Veröffentlichung der Apple Vision Pro, die Herausforderungen von WeWork und Alibaba sowie die Frage, wie weit der KI-Trend wirklich geht. Unsere Investmentideen der Woche, Flixmobility und Fortinet, bieten spannende Perspektiven für Anleger, die am Puls der Zeit bleiben wollen. Verpassen Sie nicht unsere tiefgehenden Analysen und Einsichten in die Dynamik des Aktienmarkts.

Carl Quintanilla, Jim Cramer and David Faber explored what to expect from the markets after new record highs were set on Friday. The anchors offered reaction to Fed Chair Powell's “60 Minutes” interview. Caterpillar CEO Jim Umpleby joined the program exclusively to discuss quarterly results that propelled the stock to fresh record highs. Carl, Jim and David also discussed Tesla shares extending their 2024 slide -- after the Wall Street Journal reported that Elon Musk took drugs with some Tesla board members, according to the paper's sources. Also in focus: Meta's historic Friday $200 billion market cap rally, McDonald's earnings. Snap and Estee Lauder announce job cuts, new 737 MAX problems for Boeing, Novo Nordisk's parent buys Catalent to help expand Wegovy supply. Squawk on the Street Disclaimer

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Daniel Eckert und Holger Zschäpitz über Turbulenzen bei Boeing, einen Mega-Aktienrückkauf bei Qiagen und was sonst noch wichtig wird in dieser Woche. Außerdem geht es um Nvidia, Alaska Airlines, United Airlines, Catalent, Bitcoin, Invesco Nasdaq Biotech ETF (WKN: A12CCJ), iShares Nasdaq Biotechnology (WKN: A2DWAW), AstraZeneca, Amgen, Sanofi, Gilead, Biogen, Moderna, Biontech, Genmab, Atai Life Science, Global X Genomics & Biotechnology (WKN: A2QRCP), Bristol Meyers-Squib, BB Biotech. Wir freuen uns über Feedback an aaa@welt.de. Ab sofort gibt es noch mehr "Alles auf Aktien" bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Good morning from Pharma and Biotech daily, the podcast bringing you crucial updates from the Pharma and Biotech world. Today's episode covers several significant developments and deals in the industry.AstraZeneca is on the verge of acquiring vaccine maker Icosavax for up to $1.1 billion. This move underscores AstraZeneca's dedication to vaccine development, particularly as it gains a combination vaccine targeting respiratory viruses. This acquisition is timely, considering the looming expiration of patents for several major medicines, a challenge prompting big pharma to explore new markets.In a notable development, Bristol Myers Squibb (BMS) has acquired rights to develop and commercialize Systimmune's antibody-drug conjugate (ADC) for various cancers, including lung and breast cancer. The deal, potentially worth $8.4 billion, highlights the growing interest in ADCs, a promising class of cancer treatments.Sanofi has terminated its licensing agreement with Maze Therapeutics for a Pompe disease drug following challenges from the US Federal Trade Commission (FTC). The decision to end this deal reflects the heightened regulatory scrutiny within the industry.Reiterating its focus on vaccines, AstraZeneca has also acquired Icosavax in a deal potentially worth $1.1 billion. This acquisition enables AstraZeneca to enter the market for respiratory syncytial virus vaccines, demonstrating its commitment to expanding its vaccine portfolio.In a major industry move, Pfizer's $43 billion acquisition of Seagen has overcome regulatory barriers and is set to conclude. This deal, the largest in recent years, will significantly enhance Pfizer's presence in the ADC market, a trend indicative of the current wave of large-scale acquisitions in pharma.Sino Biological, a biotech firm, has made strides in gene therapy by developing platforms for multi-pass transmembrane protein products. These advancements underscore the industry's progress in drug manufacturing technologies.Employee engagement is gaining importance in the sector, as illustrated by Kyowa Kirin's new program aimed at involving its workforce in shaping the company's future. This approach reflects a broader understanding of the role of employee involvement in fostering innovation and success.Tome Biosciences has launched with a significant funding of $213 million, focusing on genomic medicines, particularly in precision oncology. This move highlights the ongoing advancements in gene therapy and personalized medicine.At the American Society of Hematology (ASH) annual meeting, BMS and 2seventy Bio presented promising survival data for their CAR-T therapy, Abecma, used in treating multiple myeloma. This data points to the potential of CAR-T therapy in treating complex diseases.Novartis' iptacopan showed positive results in a Phase III study for an ultra-rare kidney disease. Coming shortly after FDA approval for another indication, this demonstrates progress in treating rare diseases.Catalent is seeking to expand in the GLP-1 market, used in treating type 2 diabetes, amid a revenue downturn and staff cuts. This move reflects the competitive nature of the diabetes treatment market.The Centers for Medicare and Medicaid Services (CMS) are preparing to announce the 'maximum fair price' for drugs under the Inflation Reduction Act's negotiation program. This impending decision is poised to be a pivotal pharmaceutical trend in 2024, with significant political and economic implications, especially considering the upcoming presidential election.The year 2023 saw four historic FDA approvals, including a vaccine for RSV and a drug for Alzheimer's disease, showcasing ongoing progress in drug development and healthcare.Bryter's insights have been instrumental in pharma's success in marketing rare disease treatments, highlighting the vital role of data analytics and strategic insights in effective marketin

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Tim Scott, President and CEO, AustinPx. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tim, covering:  The founding story of Pharmatek, and how client centricity and ‘training the hell out of the team' contributed to the growth How the niche of being a spray drying expert led to a sale of Pharmatek to Catelent... and why he didn't last very long post-acquisition The disruptive technology and team that got Tim so excited... he came back to the ‘CDMO+' world in Austin Building traction for a game-changing technology for poorly soluble compounds to get it into 100 molecules and commercial products Tim brings more than twenty years of pharmaceutical contract development and manufacturing organization (CDMO) leadership experience. Previously, Mr. Scott was co-founder and president of Pharmatek Laboratories, a CDMO where he led the growth and ultimate sale of the company to Catalent. He currently serves on the boards of multiple organizations, including Avelas Biosciences, DTx Pharma, CONNECT, BIOCOM, and the University of California, San Diego's Dean's Advisory Council for the Division of Biological Sciences. He previously served on the board of Zacharon Pharmaceuticals (sold to BioMarin in 2014). At UC San Diego, Tim has founded or supported multiple biotech spinouts including Zacharon, TEGA therapeutics, LipoNexus, Knoubis Bio, Nerio and Augment Biosciences. Mr Scott earned his BA in Biochemistry from UC San Diego and his JD from the University of San Diego. He is a member of the California Bar. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.  

Revenge of the Nerds - From Victim to VillainWebsite: http://www.battle4freedom.comNetwork: https://www.mojo50.comStreaming: https://www.rumble.com/c/Battle4FreedomStreaming LIVE on RUMBLE @ https://rumble.com/v32vv1c-revenge-of-the-nerds-from-victim-to-villain.htmlhttps://www.dailymail.co.uk/news/article-12344483/Indiana-boy-shooting-toddler-brother-parents-charged-Deonta-Johnson-Shatia-Welch.htmlBoy, 5, high on COCAINE fatally shoots his 16-month-old brother who was high on marijuana inside Indiana home: Parents are charged with neglect-Isiah Johnson, 16 months, was shot in the head by his older brother in Indiana in March at his family's home-Their father, Deonta Johnson, 27, was asleep at the time of the shooting-Both parents have now been charged with felony neglect by authorities https://babylonbee.com/news/experts-warn-we-have-only-12-years-left-until-they-change-the-dates-on-global-warming-againExperts Warn We Have Only 12 Years Left Until They Change The Timeline On Global Warming Againhttps://www.dailymail.co.uk/health/article-12339279/Covid-vaccine-myocarditis-heart-Elon-Musk-bronny-james.htmlThe truth about myocarditis and Covid vaccines: After Bronny James' cardiac arrest and Elon Musk pushing anti-vaxx theory, leading doctors insist jabs are NOT to blameData shows people aren't dying from the jabs despite anti-vaxx claimshttps://www.dailymail.co.uk/health/article-12343007/Wegovy-weight-loss-injection-factory-plagued-sterile-safety-failures.htmlContamination fears at Wegovy factory as FDA finds serious safety and infection control failings at plant that makes weight-loss injection pens-Catalent in Brussels, Belgium makes self-injection pens for Wegovy/Ozempic-Poor air filtration systems meant that sterility was 'compromised', docs showhttps://www.dailymail.co.uk/news/article-12343679/Russia-accused-creating-fake-body-cam-videos-Ukrainian-troops-dying-trenches-cynical-social-media-propaganda-war.htmlRussia is accused of creating fake body-cam videos of Ukrainian troops dying in the trenches as part of cynical social media propaganda war-The egregious social media propaganda campaign has been torn to shreds-Analysts pointed out a series of markers revealing the soldiers' crude fakery https://www.dailymail.co.uk/news/article-12344087/Ukrainian-fencing-star-refuses-shake-hands-Russian-opponent.htmlVictorious Ukrainian fencing star refuses to shake hands with Russian opponent - and is then DISQUALIFIED after rival stages sulking hour-long protest-Olha Kharlan faced off against Russian Anna Smirnova on Thursday in Milan-Ukrainian beat opponent, but pointedly refused to shake her hand in protest https://www.dailymail.co.uk/news/article-12344737/The-ten-cities-home-foreclosures-rising-fastest-amid-concerns-owners-sitting-negative-equity-timebomb.htmlRevealed: The ten US cities where home foreclosures are rising fastest - amid concerns owners are sitting on a 'negative equity timebomb'-Home foreclosures have shot up for the second year in a row, figures show-Atlantic City, New Jersey, has seen the biggest jump in repossessionshttps://www.dailymail.co.uk/news/article-12343075/Anheuser-Busch-lay-HUNDREDS-employees-wake-Dylan-Mulvaney-scandal-saw-Bud-Light-lose-title-selling-beer-Modelo.htmlAnheuser-Busch to lay off hundreds of employees after Bud Light and Dylan Mulvaney disaster-Anheuser-Busch announced the decision to lay off about two percent of its US workforce in a statement released by CEO Brendan Whitworth on Wednesday-The workforce makes up about 19,000 employees, according to its website, meaning around 380 workers will be impacted -'These corporate structure changes will enable our teams to focus on what we do best—brewing great beer for everyone,' Whitworth saidhttps://www.dailymail.co.uk/news/article-12345619/url-Ethan-Crumbley-Michigan-oxford-shooting-sentencing-journal-pretty-girl-family.htmlMichigan school shooter Ethan Crumbley, 15, drew disturbing image in journal of girl with gun to her head saying his first victim needed to be 'pretty' and 'suffer just like me': Family sees video of deadly rampage as judge mulls life sentence-Michigan high school shooter Ethan Crumbley appeared in court on Thursday-Prosecutors presented his chilling diary and evidence photos from the scene-Judge will decide whether the teen gets life in prison or a chance at parole ANTI-TRUMP or ANTI-BULLY???https://www.forbes.com/real-time-billionaires/#49f726893d78THE WORLD'S REAL-TIME BILLIONAIREShttps://www.businessinsider.com/steve-jobs-was-richer-than-these-14-top-ceos-at-age-25-but-not-mark-zuckerberg-2011-10Steve Jobs Was Richer Than These 12 Tech Visionaries At Age 25https://www.forbes.com/sites/theyec/2022/05/24/nine-effective-ways-to-build-a-thicker-skin-as-an-entrepreneur/?sh=7d45974114b1Nine Effective Ways To Build A 'Thicker Skin' As An Entrepreneur1. Separate Your Self-Worth From Your Business2. Compare The Two Versions Of You3. Realize You Can't Please Everyone4. Make Yourself Uncomfortable5. Set A Time Limit For Mourning6. Focus On Growing7. Reconnect With Your 'Why'8. Let Go Of Perfection9. Reflect On Your SuccessesSpecial Message

Auto theft in U.S. cities soared during the first half of the year. Activist investor Elliott takes a big stake in drugmaker Catalent. Keith Collins hosts. Learn more about your ad choices. Visit megaphone.fm/adchoices

Carl Quintanilla, Jim Cramer and David Faber explored what to expect from the markets this week, with key inflation data, the debt limit standoff and earnings in the mix. The anchors discussed Treasury Secretary Janet Yellen's warning of "economic chaos" and a constitutional crisis if Congress fails to lift the debt ceiling. Carl, Jim and David also reacted to comments Warren Buffett made Saturday at Berkshire Hathaway's annual shareholder meeting -- everything from the banking crisis to the strength of Apple. Also in focus: Stifel ups its S&P 500 price target to 4,400, PacWest extends its rebound after announcing a dividend cut, Catalent sinks, Cramer on Nelson Peltz and Estee Lauder.  Squawk on the Street Disclaimer